Cargando…

Comparison of Hospital Length of Stay and Supportive Care Utilization Between Patients Treated with CPX-351 and 7+3 for Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes

PURPOSE: CPX-351 is dual-drug liposomal encapsulation of daunorubicin and cytarabine at a fixed synergistic 1:5 molar ratio. This study determined current real-world use of CPX-351 versus conventional 7+3 (cytarabine+daunorubicin) therapy and evaluated hospital length of stay (LOS) and supportive ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Price, Kwanza, Cao, Zhun, Lipkin, Craig, Profant, Deb, Robinson, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754465/ https://www.ncbi.nlm.nih.gov/pubmed/35035224 http://dx.doi.org/10.2147/CEOR.S342303

Ejemplares similares

CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
por: Rautenberg, Christina, et al.
Publicado: (2021)

Acute myeloid leukemia with myelodysplasia-related changes and basophilic differentiation
por: Rieu, Jean-Baptiste, et al.
Publicado: (2020)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

CPX‐351 (Vyxeos(®)) can cause severe rash in acute myeloid leukemia—A case report
por: Urbantat, Ruth M., et al.
Publicado: (2021)

TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia
por: Testa, Ugo, et al.
Publicado: (2023)

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
por: Vucinic, Vladan, et al.
Publicado: (2020)

Successful Treatment of Acute Myeloid Leukemia with CPX-351 in 2 Patients in the United Kingdom during the COVID-19 Pandemic
por: Munisamy, Sreetharan, et al.
Publicado: (2021)

P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA
por: Mitchell, Joshua D., et al.
Publicado: (2023)

Genetic Characteristics According to Subgroup of Acute Myeloid Leukemia with Myelodysplasia-Related Changes
por: Kang, Dain, et al.
Publicado: (2022)

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
por: McCarter, Joseph G. W., et al.
Publicado: (2023)

Acute myeloid leukemia with myelodysplasia-related changes and blasts of the mixed T/myeloid phenotype: a case report
por: Sheng, Xian-Fu, et al.
Publicado: (2022)

Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases
por: Vanegas, Yenny Alejandra Moreno, et al.
Publicado: (2018)

PB1823: SECONDARY ACUTE MYELOID LEUKEMIA AND DE NOVO ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES DISTINCT LANDSCAPE, OR THE SAME DISEASE?
por: Jagurinoski, M., et al.
Publicado: (2022)

Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC)
por: Arber, Daniel A, et al.
Publicado: (2020)

Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience
por: Fianchi, Luana, et al.
Publicado: (2023)

Myelodysplasia-Related Features of Acute Myeloid Leukemia Evolving From Philadelphia-Negative Myeloproliferative Neoplasms
por: Kim, Jae-Ryuk, et al.
Publicado: (2016)

Acute Myeloid Leukemia with Myelodysplasia-Related Changes in a Patient with Crohn's Disease Treated with Immunosuppressive Therapy
por: Li, Bowen, et al.
Publicado: (2018)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies
por: Hu, Yixin, et al.
Publicado: (2022)

Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
por: Bernal, Teresa, et al.
Publicado: (2023)

ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia‐related changes and normal karyotype
por: Prats‐Martín, Concepción, et al.
Publicado: (2020)

The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation †
por: Wang, Yi, et al.
Publicado: (2022)

P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
por: Luca Morelli, Gian, et al.
Publicado: (2023)

Successful outcome of Langerhans cell histiocytosis complicated by therapy-related myelodysplasia and acute myeloid leukemia: a case report
por: Al-Anazi, Khalid A, et al.
Publicado: (2008)

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
por: Devillier, Raynier, et al.
Publicado: (2015)

Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia
por: Cardoso, S R, et al.
Publicado: (2016)

Acute abdominal pain due to atypical bilateral adrenal infarction in acute myeloid leukemia with alterations related to myelodysplasia: A case report
por: Hirata, Risa, et al.
Publicado: (2023)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

P486: REAL-WORLD EFFECTIVENESS AND SAFETY OF CPX-351 IN PATIENTS AGED <60 AND ≥60 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: CREST-UK POST-HOC ANALYSIS
por: Mehta, Priyanka, et al.
Publicado: (2023)

P2RY8-CRLF2 Fusion–Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel Therapy
por: Aypar, Umut, et al.
Publicado: (2020)

Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting
por: Nakaya, Aya, et al.
Publicado: (2020)

Immunomodulatory Effect of Green Tea Treatment in Combination with Low-dose Chemotherapy in Elderly Acute Myeloid Leukemia Patients with Myelodysplasia-related Changes
por: Calgarotto, Andrana K., et al.
Publicado: (2021)

Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients
por: Wang, Lei, et al.
Publicado: (2021)

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
por: Lin, Tara L., et al.
Publicado: (2019)

Clinical Experience Using Vitamin D and Analogs in the Treatment of Myelodysplasia and Acute Myeloid Leukemia: A Review of the Literature
por: Harrison, Jonathan S., et al.
Publicado: (2012)

Transforming activities of the NUP98-KMT2A fusion gene associated with myelodysplasia and acute myeloid leukemia
por: Fisher, James N., et al.
Publicado: (2020)

Acute Myeloid Leukemia
Publicado: (2019)

Acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_75o8kff2krvfsch7g2ilaqdi27